Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Inclusion Criteria: * Ability to understand and provide informed consent. * Willingness and ability to comply with scheduled study visits and procedures. * Adult men or women age ≥ 18 years. * Histologic or cytologic diagnosis of advanced/metastatic Non-small Cell Lung Cancer (NSCLC), stage IIIB/IV. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * 1 - 3 (no more than three) prior regimens for stage IIIB/IV disease, with at least one prior regimen (for any stage) containing a platinum-based agent. One prior PD-1 or PD-L1 antibody-based regimen is allowable and counts as a prior regimen. Prior therapy with a taxane is allowed. * Participants enrolled on the phase 1b expansion portion of the trial must be willing and able to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 3 months prior to initiation of treatment on Day 1, and must be obtained after most recent tumor progression. Participants for whom newly-obtained samples cannot be provided (e.g., inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the Sponsor. * Prior radiation is allowed if patients have recovered from side effects. * Potential participants with a prior history of brain metastases are eligible, provided: * The brain metastases have been treated * The patient is asymptomatic from the brain metastases * Corticosteroids prescribed for the ma…